Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Cancer Res. 2010 Dec 15;16(24):5923-7. doi: 10.1158/1078-0432.CCR-10-0728. Epub 2010 Nov 8.

Pazopanib in renal cell carcinoma.

Author information

1
University of Chicago, Chicago, Illinois 60637, USA.

Abstract

Pazopanib is an oral, multitargeted tyrosine kinase inhibitor that has been approved by the U.S. Food and Drug Administration for treatment of patients with advanced renal cell cancer on the basis of a randomized, double-blind, placebo-controlled, phase III trial, which showed that once a day dosing of 800 mg of pazopanib resulted in progression free survival of 9.2 months versus 4.2 months (P < 0.0001). Pazopanib thus joins sorafenib and sunitinib as one of the clinically available VEGF receptor (VEGFR)-targeted drugs for the treatment of patients with advanced clear cell renal cell cancer. The mechanism of action, preclinical and clinical data, and a comparison with the other drugs in its class are outlined below.

PMID:
21059813
DOI:
10.1158/1078-0432.CCR-10-0728
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center